显著延长癌症患者总生存期！罗氏(RHHBY.US)双特异性抗体达3期主要终点

智通财经04-16

智通财经APP获悉，4月16日，罗氏(RHHBY.US)宣布其3期试验STARGLO达到总生存期(OS)主要终点。分析显示，与活性对照药物相较，使用其双特异性抗体Columvi(glofitamab)联合吉西他滨和奥沙利铂治疗的复发或难治性(R/R)弥漫性大B细胞淋巴瘤(DLBCL)患者的生存期显著延长，这些患者之前至少接受过一线治疗，并且不适合进行自体干细胞移植。该数据将提交给监管单位并在即将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2427822838?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-16 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2427822838","market":"sh","top_or_hot":-1,"title":"显著延长癌症患者总生存期！罗氏(RHHBY.US)双特异性抗体达3期主要终点","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，4月16日，罗氏(RHHBY.US)宣布其3期试验STARGLO达到总生存期(OS)主要终点。分析显示，与活性对照药物相较，使用其双特异性抗体Columvi(glofitamab)联合吉西他滨和奥沙利铂治疗的复发或难治性(R/R)弥漫性大B细胞淋巴瘤(DLBCL)患者的生存期显著延长，这些患者之前至少接受过一线治疗，并且不适合进行自体干细胞移植。该数据将提交给监管单位并在即将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1103564.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>显著延长癌症患者总生存期！罗氏(RHHBY.US)双特异性抗体达3期主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n显著延长癌症患者总生存期！罗氏(RHHBY.US)双特异性抗体达3期主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-16 21:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1103564.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，4月16日，罗氏(RHHBY.US)宣布其3期试验STARGLO达到总生存期(OS)主要终点。分析显示，与活性对照药物相较，使用其双特异性抗体Columvi(glofitamab)联合吉西他滨和奥沙利铂治疗的复发或难治性(R/R)弥漫性大B细胞淋巴瘤(DLBCL)患者的生存期显著延长，这些患者之前至少接受过一线治疗，并且不适合进行自体干细胞移植。该数据将提交给监管单位并在即将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1103564.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1103564.html","article_id":"2427822838","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427822838","pubTimestamp":1713273020,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，4月16日，罗氏宣布其3期试验STARGLO达到总生存期主要终点。分析显示，Columvi组合疗法可显著延长患者总生存期，且该组合疗法的安全性与各个组分的已知安全性一致。根据新闻稿，Columvi是首个获得美国FDA加速批准和欧盟委员会有条件上市的固定时间治疗的双特异性抗体，用于治疗接受过两线或两线以上全身治疗的R/R DLBCL患者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"RHHBY":"罗氏控股","BK4007":"制药","03165":"华夏欧优股对冲"},"translate_title":"Significantly prolong the overall survival of cancer patients! Roche (RHHBY.US) bispecific antibody reaches phase 3 primary endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":1,"03165":0.6},"content_text":"智通财经APP获悉，4月16日，罗氏(RHHBY.US)宣布其3期试验STARGLO达到总生存期(OS)主要终点。分析显示，与活性对照药物相较，使用其双特异性抗体Columvi(glofitamab)联合吉西他滨和奥沙利铂治疗的复发或难治性(R/R)弥漫性大B细胞淋巴瘤(DLBCL)患者的生存期显著延长，这些患者之前至少接受过一线治疗，并且不适合进行自体干细胞移植。该数据将提交给监管单位并在即将召开的医学会议上分享。据悉，STARGLO是一项多中心、开放标签、随机3期研究，旨在评估Columvi联合吉西他滨加奥沙利铂与利妥昔单抗联合奥沙利铂相比，对已接受过至少一线治疗且不适合进行自体干细胞移植的DLBCL患者的疗效和安全性。分析显示，Columvi组合疗法可显著延长患者总生存期，且该组合疗法的安全性与各个组分的已知安全性一致。根据新闻稿，Columvi是首个获得美国FDA加速批准和欧盟委员会有条件上市的固定时间治疗的双特异性抗体，用于治疗接受过两线或两线以上全身治疗的R/R DLBCL患者。该批准是基于Columvi作为单药在关键1/2期研究NP30179中所取得的积极结果。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427822838"}